Pharmacogenomics holds promise for enhancing drug safety and efficacy, paving the way for more precise, patient-centred therapeutic approaches supporting prevention in public health. However, its integration into routine healthcare remains limited across Europe. A European multidisciplinary expert pharmacoeconomic workshop was held in Amsterdam in January 2025, to share experiences and define priorities in the face of challenges for the integration of pharmacogenomics testing. The European expert workshop brought together 55 participants from 10 countries, including 14 speakers representing policy, healthcare, academia, patient representation and industry.
Based on expert discussions, five key challenges and priorities were identified for advancing pharmacogenomics: 1) robust health economic evaluations to support funding decisions, 2) targeted education and training for healthcare professionals, and raising public and healthcare professional awareness of pharmacogenomics testing, 3) investment in ICT and data infrastructure to support data access and sharing, 4) development of clear policies, and stronger cross-border collaboration and 5) equitable access and scalable integration of testing.
Overcoming barriers such as reimbursement issues, policy misalignment, and regional differences will require coordinated, multi-stakeholder efforts guided by informative indicators and (health) impact assessments. Moving forward, collaboration throughout the implementation pathway will be crucial to advance pharmacogenomic testing as key part of personalised prevention in public health enhancing treatment efficacy and preventing medication-related harm.